Barocelli Elisabetta, Ballabeni Vigilio, Manenti Veronica, Flammini Lisa, Bertoni Simona, Morini Giovanni, Comini Mara, Impicciatore Mariannina
Dipartimento di Scienze Farmacologiche, Biologiche e Chimiche Applicate, Università di Parma, Parco Area delle Scienze 27/a, 43100 Parma, Italy.
Pharmacol Res. 2006 Mar;53(3):226-32. doi: 10.1016/j.phrs.2005.11.004. Epub 2005 Dec 20.
The histamine H3 receptor subtype negatively modulates the release of various neurotransmitters such as histamine, glutamate, norepinephrine, acetylcholine and many others mainly in the CNS and H3 antagonists have been developed to treat central diseases characterized by neurotransmission disturbance such as schizophrenia, memory/learning and sleep disorders. In search for non-imidazole histamine H3 receptor antagonists, currently indicated as a promising class of H3 blockers, a series of simple alkylpiperidine derivatives has been studied to attain a preliminary pharmacological profile. The compounds were characterized in vitro in terms of binding affinity, antagonistic potency and selectivity at rodent H3 receptors. The imidazole-free derivatives possessed moderate to pronounced antagonistic potency at guinea-pig ileal H3 receptor consistent with binding affinity at rat brain H3 receptors and showed a favourable receptor selectivity profile. For the compound 5, with the highest affinity at rat H3 receptors, comparable values were calculated in binding (pKi = 8.35) and functional (pA2 = 8.22) assays in SK-N-MC cells stably expressing human H3 receptors. These findings indicate to extend the investigation to pharmacokinetic property and central effects to gain deeper knowledge on the pharmacological potential of this compound.
组胺H3受体亚型主要在中枢神经系统中对多种神经递质如组胺、谷氨酸、去甲肾上腺素、乙酰胆碱等的释放起负性调节作用,并且已开发出H3拮抗剂来治疗以神经传递紊乱为特征的中枢疾病,如精神分裂症、记忆/学习障碍和睡眠障碍。为了寻找非咪唑类组胺H3受体拮抗剂(目前被认为是一类有前景的H3阻滞剂),已对一系列简单的烷基哌啶衍生物进行了研究,以获得初步的药理学特征。这些化合物在体外通过对啮齿动物H3受体的结合亲和力、拮抗效力和选择性进行了表征。无咪唑衍生物在豚鼠回肠H3受体上具有中度至显著的拮抗效力,这与在大鼠脑H3受体上的结合亲和力一致,并且显示出良好的受体选择性特征。对于在大鼠H3受体上具有最高亲和力的化合物5,在稳定表达人H3受体的SK-N-MC细胞中的结合试验(pKi = 8.35)和功能试验(pA2 = 8.22)中计算出了相当的值。这些发现表明应将研究扩展到药代动力学性质和中枢效应,以更深入地了解该化合物的药理学潜力。